Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Galmed Reports Results From The Open-label Part Of The ARMOR Study

Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) reduction in
byBenzinga Newsdesk
January 4, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) reduction in fibrosis score demonstrated using AI-assisted, digital pathology reading
  • Highly statistically significant (p<0.0001) reduction in liver stiffness by Fibroscan
  • Highly statistically significant (p<0.0001) reduction in biochemical markers of liver injury ALT and AST
  • Highly statistically significant reductions in major fibrosis biomarkers: FIB-4 (p<0.0001), Pro-C3 (p<0.0001) and ELF (p= 0.0038) at week 24
  • Galmed is submitting all data to the FDA to initiate discussions on incorporating more sensitive histology reading methodologies as primary endpoints in NASH clinical studies and is actively looking for partnering opportunities to continue Aramchol’s clinical development.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

OPKO Health And 2 Other Penny Stocks Insiders Are Aggressively Buying

By Lisa Levin
May 9, 7:53 AM
The Dow Jones closed lower on Monday after recording sharp gains on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

FOMC